Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.

CYB003/CYB004 clinical catalysts into 2026, $248M cash runway, equity raises risk, valuation optionality. Click for this CYBN ...

Transformative Growth Counseling is accepting applications for its master’s-level internship program, supporting workforce development and future clinicians. NAPERVILLE, IL, UNITED STATES, December 30 ...

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

In the past decade, we have seen tremendous advances in the prevention, treatment and management of chronic kidney disease ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...

OneOncology supports 33 practices, providing infrastructure and expertise for advanced therapies and value-based care, while ...

Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...

The NYU Langone Research Community Development team fosters mentorship, professional growth, and inclusive engagement for ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology * Lead progra ...

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 ...